Tasimelteon Patent Expiration

Tasimelteon is Used for treating nighttime sleep disturbances in Smith-Magenis syndrome and non-24-hour sleep-wake disorder with tasimelteon. It was first introduced by Vanda Pharmaceuticals Inc in its drug Hetlioz on Jan 31, 2014. Another drug containing Tasimelteon is Hetlioz Lq. 4 different companies have introduced drugs containing Tasimelteon.


Tasimelteon Patents

Given below is the list of patents protecting Tasimelteon, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Hetlioz US10071977 Highly purifid pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz US10149829 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US10179119 Method of treatment Aug 29, 2035 Vanda Pharms Inc
Hetlioz US10376487 Method of treatment Jul 27, 2035 Vanda Pharms Inc
Hetlioz US10449176 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US10610510 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US10610511 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz US10829465 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz US10945988 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US10980770 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11141400 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz US11266622 Method of treatment Aug 29, 2035 Vanda Pharms Inc
Hetlioz US11285129 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11566011 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz US11633377 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11759446 Liquid tasimelteon formulations and methods of use thereof Feb 21, 2041 Vanda Pharms Inc
Hetlioz US11760740 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz US11786502 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz US11826339 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11833130 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11850229 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11918556 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US11918557 Treatment of circadian rhythm disorders Apr 07, 2033 Vanda Pharms Inc
Hetlioz US5856529 Benzofuran and dihydrobenzofuran melatonergic agents Dec 09, 2022

(Expired)

Vanda Pharms Inc
Hetlioz US8785492 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US9060995 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US9539234 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US9549913 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz US9730910 Treatment of circadian rhythm disorders May 17, 2034 Vanda Pharms Inc
Hetlioz US9855241 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz USRE46604 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US10071977 Highly purifid pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz Lq US10149829 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US10179119 Method of treatment Aug 29, 2035 Vanda Pharms Inc
Hetlioz Lq US10376487 Method of treatment Jul 27, 2035 Vanda Pharms Inc
Hetlioz Lq US10610510 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US10610511 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz Lq US10829465 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz Lq US10980770 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11141400 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz Lq US11202770 Liquid tasimelteon formulations and methods of use thereof Dec 11, 2040 Vanda Pharms Inc
Hetlioz Lq US11266622 Method of treatment Aug 29, 2035 Vanda Pharms Inc
Hetlioz Lq US11285129 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11566011 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz Lq US11633377 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11759446 Liquid tasimelteon formulations and methods of use thereof Feb 21, 2041 Vanda Pharms Inc
Hetlioz Lq US11760740 Highly purified pharmaceutical grade tasimelteon Feb 12, 2035 Vanda Pharms Inc
Hetlioz Lq US11786502 Method of treatment Oct 10, 2034 Vanda Pharms Inc
Hetlioz Lq US11826339 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11833130 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11850229 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11918556 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US11918557 Treatment of circadian rhythm disorders Apr 07, 2033 Vanda Pharms Inc
Hetlioz Lq US5856529 Benzofuran and dihydrobenzofuran melatonergic agents Dec 09, 2022

(Expired)

Vanda Pharms Inc
Hetlioz Lq US9539234 Treatment of circadian rhythm disorders Jan 25, 2033 Vanda Pharms Inc
Hetlioz Lq US9730910 Treatment of circadian rhythm disorders May 17, 2034 Vanda Pharms Inc


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳

Tasimelteon Generics

Several generic applications have been filed for Tasimelteon. The first generic version for Tasimelteon was by Teva Pharmaceuticals Usa Inc and was approved on Dec 12, 2022. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Jan 12, 2023.

Given below is the list of companies who have filed for Tasimelteon generic.


1. MSN

Msn Laboratories Private Ltd has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG capsule Prescription ORAL AB Jan 12, 2023


2. APOTEX

Apotex Inc has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG capsule Prescription ORAL AB Dec 20, 2022


3. TEVA PHARMS USA INC

Teva Pharmaceuticals Usa Inc has filed for 1 generic for Tasimelteon. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG capsule Prescription ORAL AB Dec 12, 2022